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1. INTRODUCTION 
Infection of cells by enveloped viruses such as 
Sendai virus consists of two steps: 
(1) 
(2) 
Binding of the particles to cell surface receptors, 
mainly sialoglycoproteins and sialoglycolipids 
]1,21; 
Fusion of the viral envelopes with the recipient 
cell plasma membranes, with the concomitant 
injection of the viral nucleocapsid into the intra- 
cellular space of the cell [2]. 
Membrane vesicles made of phospholipid bi- 
layers, in which Sendai virus envelope glycopro- 
teins are incorporated, are fusogenic [3-51. Such 
reconstituted envelopes of Sendai virus can serve, as 
do phospholipid liposomes [6], as a vehicle to in- 
troduce macromolecules into living mammalian 
cells. Indeed, loaded fusogenic vesicles have been 
used as a vehicle to introduce both proteins [5] and 
DNA molecules into the appropriate cells 171. Since 
sialic acid residues, which serve as virus receptors, 
are present on plasma membranes of a wide variety 
of cells, virus particles or its reconstituted envelopes 
can serve almost as a ‘universal syringe’. 
For certain purposes, however, and especially for 
the future use of fusogenic vesicles for drug and 
gene therapy, it is of paramount importance to 
develop a fusogenic vesicle which will be able to 
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attach and to fuse with only specific cells. Such 
‘targeted’ fusogenic vesicles can probably be ob- 
tained by covalently binding specific antibodies to 
the virus surface. Attachment of specific antibodies 
to phospholipid liposomes [8] or to erythrocyte 
membranes [9] has been reported. 
Here, we describe binding of specific antibodies 
to envelopes of intact Sendai virus particles. Virus 
particles to which anti-human erythrocyte anti- 
bodies are attached, agglutinate and hemolyse 
neuraminidase-treated human erythrocytes, namely, 
erythrocytes from which native virus receptors 
have been removed [ 11. 
2. MATERIALS AND METHODS 
Sendai virus was propagated in the allantoic fluid 
of lo-day-old embryos, and was purified and 
determined as in [lo]. 
Human erythrocytes (type O+, aged 3-6 weeks) 
were washed with solution A (150 mM NaCl, 
20 mM tricine-NaOH (pH 7.4)) as in [ 111. 
Human erythrocytes were treated with neur- 
aminidase (Boehringer, Cl. perfringens) as in [ 121. 
Briefly, the cells were washed in isotonic solution 
containing 150 mM NaCl, 10 mM NaPi (pH 7.4) 
then washed twice with a solution of 150 mM NaCl 
and 40 mM sodium acetate (pH 5.7) which con- 
tained 5 mM CaC12. The pellet obtained was sus- 
pended in the above acetate buffer to give a cell 
suspension of 35-40s (v/v). Then, to each 1 ml cell 
suspension, 15 ~1 neuraminidase solution (0.6 
U/mg, 1 mg/ml) was added and the suspension was 
incubated for 2 h at 37°C with gentle shaking. After 
washing with solution A, the neuraminidase-treated 
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Fig. 1. Schematic summary of the method for coupling 
IgG molecules to Sendai virus particles. See section 2 for 
composition of solution A 
cells were suspended in solution A to give a cell 
suspension of 35-40s (v/v). 
Reduction of Sendai virus with dithiothreitol 
(DTT) was performed as follows (see also fig.1): A 
virus suspension (3 mg/ml in solution A) was first 
sonicated briefly (2-3 min in bath sonicator) then 
centrifuged to remove large virus clumps (2000 
rev./min, 10 min at room temperature). To the 
supernatant, DTI was added to 1 mM final cont. 
and the virus mixture was incubated for 1 h at 37°C 
with gentle shaking. The reduced virus was then 
dialysed at 4°C for 48 h in Spectrophore 2 tubing 
against solution A with 3 changes of the buffer. 
The coupling procedure between reduced virus 
and immunoglobulin (IgG) is described in fig. 1 and 
[9]. 21 pg or 42 pg N-succinimidyl-3-(2-pyridyl- 
dithio)-propionate (SPDP), dissolved in dimethyl 
sulfoxide (1 mg/ml), was mixed under vortexing 
with 2 mg purified IgG dissolved in 1 ml/20 mM 
sodium phosphate buffer (pH 8.0). After 20 min 
incubation, the mixture was chromatographed on 
Sephadex G-25 columns (12 x 60 mm) to remove 
the unreacted SPDP. Then, the IgG containing 
2-pyridyl disulphide (IgG-PFP) moiety (0.4- 1.2 
mg), was incubated for 1 h at room temperature 
with the reduced virus (2.6 mg). The IgG-coupled 
virus particles were collected by centrifugation and 
the pellet obtained was suspended in solution A to 
give 2-3 mg protein/ml. Assays of agglutination, 
hemolysis and fusion of human erythrocytes pro- 
moted by Sendai virus particles were as in [ 111. 
Rabbit human erythrocyte antisera and anti- 
Sendai virus antisera were prepared as in [13] and 
the IgG fraction was obtained by fractionation of 
DEAE-cellulose column [ 141. IgG was radiolabeled 
by Na1251 using chloramine T [ 151. 
Human IgG and wheat germ agglutinin were 
from Miles Yeda, Rehovot; SPDP was from Phar- 
macia, Uppsala; DTT from Sigma, St Louis MO. 
Protein was determined by the Lowry method using 
bovine serum albumin as standard [ 161. 
3. RESULTS 
When ‘251-IgG-PDP was incubated with DTT- 
treated Sendai virus particles, a significant per- 
centage of it remained covalently attached to the 
virus particles. Whereas, when it was incubated 
Table 1 
Coupling of 1251-IgG-PDP to DTT-reduced Sendai virus 
particles 
1gG:SPDP 
System 
1251-IgG coupled 
(molar ratio) (cpm X 10 - 3, 
1:lO 
Intact virus 0.1 
D’IT-treated virus 0.1 
1:5 
Intact virus 0.2 
DTT-treated virus 42 
1:lO 
Intact virus 0.2 
DTT-treated virus 57 
In each experiment 1 mg t251-IgG-PDP (2.3 x lo5 
cpm/mg) in 1 ml 20 mM Tris-HCl buffer (pH 7.4) was 
coupled with 2.6 mg Sendai virus particles, as in section 2 
and in fig.1. The t251-IgG coupled represents the radio- 
activity recovered in the pellet after centrifugation and 
washing of t251-IgG-PDP virus particles 
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Table 2 
Biological activities of ‘targeted’ Sendai virus particles 
Treatment of 
IgG-coupled virus 
Human Erythrocytes 
Untreated Neuraminidase-treated 
Agglutination Lysis Cell-cell Agglutination Lysis 
@) fusion (W) 
Virus (native) 
Virus-SH 
Virus-SS-human IgG 
Virus-SS-anti-HE-Ab 
Virus-SS-anti-HE-Ab 
Antiviral 
antiserum 
Phenylmethylsulphonyl 
fluoride (8 mM) 
Dithiothreitol(l0 mM) 
++ 60 ++ _ _ 
- 0 nd. 0 
0 n.d. _ 0 
++ 73 + 58 
- 0 n.d. _ 0 
++ 0 n.d. + 0 
_ 0 n.d. _ 0 
Symbols: + Agglutination of 40-608 of the cells; + + Agglutination and fusion of 60-80% of the cells 
Abbreviations: virus-SH, reduced and dialysed Sendai virus particles; virus-SS-human IgG, as above 
but coupled to human IgG; virus-SS-anti-HE-Ab, as above but coupled to anti-human erythrocyte 
antibody; n.d., not determined 
Reduced and/or coupled Sendai virus particles (50 pg/system) were incubated with 2.5% (v/v) of human 
erythrocytes suspension at 37°C for 60 min. Treatments of IgG-coupled virus were performed by 
incubating 100 PLg virus-SS-anti-HE-Ab suspended in solution A, for 1 h at 37°C with the specified 
substances. Lysis of human erythrocytes by intact native virus particles was performed with 3 pg virus 
particles/system, while cell-cell fusion was induced with 20 pg/system. Cell agglutination and fusion 
were examined by phase microscopy [ 121 
with non-reduced virus particles, negligible 
amounts of IgG were conjugated with virus parti- 
cles (table 1). In addition, no binding to the virus 
particles was observed when unmodified IgG was 
incubated with the virus. Significant binding was 
observed when, under the experimental conditions 
used, the IgG-PDP was obtained by incubation of 
SPDP and IgG at a molar ratio of IgG:SPDP 
1:5-1:lO. 
The D’IT-treated and dialysed virus particles did 
not agglutinate human erythrocytes (see table 2). 
The lectin, wheat germ agglutinin (WGA), was used 
to mediate binding of the DTT-treated virus to 
human erythrocytes [3,5] and, in its presence, 
hemolysis was induced when the DTT-treated 
virus was incubated with human erythrocytes at 
37°C (fig.2). Induction of hemolysis under these 
conditions indicates the presence of a biologically 
active F-glycoprotein [2-51. 
Table 2 shows that virus particles, to which anti- 
erythrocyte antibodies are attached, agglutinate 
neuraminidase-treated erythrocytes as well as un- 
treated human erythrocytes. These results clearly 
indicate that the agglutination is mediated by the 
anti-erythrocyte antibody. No agglutination was 
observed when human erythrocytes were incubated 
with either DTT-treated virus or with virus particles 
to which human IgG was coupled. Virus particles to 
which human IgG was coupled were precipitated 
by mouse anti-human IgG antibody (not shown). 
Virus particles with attached anti-human erythro- 
cyte antibodies hemolysed untreated or neuraminid- 
ase-treated human erythrocytes (table 2). Treat- 
ment of these virus particles with either phenyl- 
methylsulfonyl-fluoride (PMSF) or DTT com- 
pletely blocked the hemolytic activity. 
As opposed to intact virus particles, IgG-coupled 
virus particles failed to induce cell-cell fusion 
254 
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VIRAL PARTICLES 
(protein ,ug/system ) 
TIME OF INCUBATION hn) 
Fig.2. (A) Hemolysis as a function of viral particle con- 
centration. WGA (2-4 gg) was added to a mixture of 
human erythrocytes and increasing amounts of DTT- 
reduced viral particles obtained after 3 days of dialysis, 
as in section 2 and fig. 1 (A). Increasing amounts of viral 
particles coupled to antihuman erythrocytes antibody 
incubated with neuraminidase-treated human erythro- 
cytes, as described in table 2 (m). (B) Hemolysis induced 
by Sendai virus particles coupled to anti-human erythro- 
cyte antibodies as a function of time. Hemolysis was 
induced by 50 pg virus, as described in table 2 and 
estimated as in 11 I]. 
(table 2). ‘Targeted’ virus particles were less active 
in inducing hemolysis than intact virus particles. 
About 50 pg antibody-coupled virus particles were 
required to obtain almost the same degree of 
hemolysis than was induced by 3 pg intact virus 
particles (table 2). 
Fig.2 shows that the hemolysis induced by virus 
particles to which anti-human erythr&yte anti- 
bodies were coupled, was dependent upon the con- 
centration of the virus particles (Gg.2A) and on the 
incubation time at 37°C (fig.2B). Addition of WGA 
to DTT-treated virus particles, although it caused 
agglutination of the cells, resulted in a much lower 
degree of hemolysis at 37°C than that obtained with 
the ‘targeted’ virus particles (fig. 1A). 
4. DISCUSSION 
Virus-induced agglutination and hemolysis of 
human erythrocytes from which the virus-receptor 
has been removed by neuraminidase treatment, was 
used here as a model system to study the activities of 
Sendai virus particles to which specific antibodies 
were attached. 
Agglutination reflects a process of virus-cell 
binding, while hemolysis occurs only after fusion of 
virus envelope with erythrocyte membrane 14,171. 
Sendai virus particles containing an active hemag- 
glutinin/neuraminidase glycoprotein (HN) but in- 
active fusion factor (F-protein), although they ag- 
glutinate human erythrocytes, they fail to hemolyse 
them [2,17,18]. Indeed, inhibitors of proteolytic en- 
zymes such as PMSF were shown to completely 
inhibit Sendai virus-induced hemolysis and cell 
fusion but not agglutination of human erythrocytes 
ll81. 
Our results indicate that: 
(i) Specific antibodies can be covalently be attach- 
ed to Sendai virus outer surface; 
(ii) In IgG-coupled virus particles, both the anti- 
body and the virus remain at least partially 
active, as shown by their ability to agglutinate 
(bind to) and to hemolyse (fuse with) 12,171 
human red blood cells from which the native 
virus receptor (sialic acid residues) was re- 
moved. 
Incubation of Sendai virus particles with low 
concentrations of DTT resulted in reversible re- 
duction of the F glycoprotein but irreversible re- 
duction of HN [ 19,201. This work shows that re- 
duced virus particles from which excess DTT was 
removed by prolonged dialysis, failed to agglutinate 
human erythrocytes but hemolysed them in the 
presence of WGA, thus indicating the presence of 
active F but inactive HN. 
We have used such DTT-reduced virus particles, 
i.e., virus with free SH (supposedly of the viral HN) 
for anchoring specific antibodies. This was done by 
first obtaining the PDP-derivatives of IgG [9] which 
were then coupled to DTT-treated virus particles. 
Hemolysis of human erythrocytes observed by 
IgG-coupled Sendai virus particles, which is subject 
to inhibition by antiviral antibodies and by phe- 
nylmethylsulfonyl-fluoride, reflects probably a 
process of virus-cell fusion [ 17,181. Experiments 
using electron microscopic techniques are under- 
way to confirm this view. However, it should be 
emphasized that the ‘targeted’ virus exhibits 
- l-10% (table 2; not shown) of the hemolytic act- 
ivity of the native, untreated virus when incubated 
with normal human erythrocytes. This may be due 
to: 
(i) Not all the reduced F molecules undergo re- 
oxidation; 
255 
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(ii) The HN molecules, besides mediating binding, 
also participate in the fusion process [ 171; 
(iii) The size of IgG avoids close association be- 
tween the viral envelope and the cell mem- 
brane. 
Although the virus particles to which anti-human 
erythrocyte antibodies are attached promote ag- 
glutination and hemolysis, they fail to induce 
cell-cell fusion, a process which is promoted by 
native virus (table 2; [ 111. This could also be due to 
the molecular size of the coupled IgG which may 
prevent tight contact between adjacent membranes, 
a step that is a prerequisite for the induction of 
cell-cell fusion [2, lo]. 
Substituting IgG with F(ab)z may provide a ‘tar- 
geted’ virus which will be able to promote cell-cell 
fusion. However, it should be emphasized that for 
the use of virus envelopes as biological carriers, an 
ideal vehicle will be a fusogenic vesicle that will fuse 
with the cells plama membrane without the induc- 
tion of cell-cell fusion. 
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